Effect of adenine arabinoside on severe Herpesvirus hominis infections in man.
D000225:Adenine / Q000008:administration & dosage / Q000627:therapeutic use; D000227:Adenine Nucleotides / Q000009:adverse effects; D001089:Arabinose / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D005831:Genital Diseases, Female / Q000188:drug therapy* / Q000382:microbiology; D006566:Herpesviridae Infections / Q000188:drug therapy*; D006801:Humans; D007165:Immunosuppression Therapy; D007231:Infant, Newborn; D007232:Infant, Newborn, Diseases / Q000188:drug therapy / Q000382:microbiology; D009059:Mouth Diseases / Q000188:drug therapy* / Q000382:microbiology; D009705:Nucleosides / Q000008:administration & dosage / Q000627:therapeutic use*; D018139:Simplexvirus / Q000302:isolation & purification; D012874:Skin Diseases, Infectious / Q000188:drug therapy / Q000382:microbiology
D000227:Adenine Nucleotides; D009705:Nucleosides; D001089:Arabinose; D000225:Adenine